Monitor for further cash runway updates and clinical milestones for CLD-401. The company's ability to fund operations beyond two months is uncertain given the going concern qualification and rapid succession of dilutive raises.
Price Chart
Executive Summary
Calidi Biotherapeutics entered into a stock purchase agreement for a registered direct offering of 1,025,640 shares at $1.17 per share, raising approximately $1.2 million in gross proceeds. The offering closed on September 21, 2026, and proceeds will be used for working capital and general corporate purposes. This capital raise follows a prior 424B5 filing just 5 days earlier, highlighting the company's ongoing need for cash as a pre-revenue biotech with a going concern qualification.
Key Facts
- Registered direct offering of 1,025,640 shares of common stock at $1.17 per share
- Gross proceeds of approximately $1.2 million
- Offering closed on September 21, 2026
- Proceeds to be used for working capital and general corporate purposes
- No underwriter or placement agent was engaged
- 45-day standstill on further equity issuances without investor consent
- 60-day lock-up agreements for directors and executive officers
- This is the second capital raise in 5 days, following a 424B5 filed September 17, 2026
Financial Impact
Approximately $1.2 million gross proceeds from sale of 1,025,640 shares at $1.17/share
Risk Factors
- Dilution from issuance of 1,025,640 new shares
- Going concern qualification indicates risk of insufficient capital to fund operations
- Second capital raise within 5 days signals acute cash needs
- Pre-revenue biotech with no approved products and significant operating losses
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043724 |
| Exhibit: ex99-1.htm | 0001493152-26-043724 |
| Exhibit: ex5-1.htm | 0001493152-26-043724 |
| Document: form8-k.htm | 0001493152-26-043724 |
| Document: 0001493152-26-043724-index-headers.html | 0001493152-26-043724 |
| Document: 0001493152-26-043724-index.html | 0001493152-26-043724 |
| Document: 0001493152-26-043724.txt | 0001493152-26-043724 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $1.07 | awaiting T+20 | — | $0.6450 (+39.72%) |
Sep 22, 2026 4w ago | 8-K | $1.09 $0.7680 | ▲ +29.54% | ▲ +30.23% | $0.6450 (+40.83%) |
Sep 17, 2026 5w ago | 424B5 | $1.10 $0.8370 | ▲ +23.91% | ▲ +24.11% | $0.6450 (+41.36%) |
Aug 13, 2026 10w ago | 8-K | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Aug 13, 2026 10w ago | Press Release | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Jun 29, 2026 16w ago | 3 | $0.1700 $0.0933 | ▼ −45.12% | ▼ −42.80% | $0.6450 (+279.41%) |
May 26, 2026 21w ago | Press Release | $2.83 $2.51 | ▼ −11.30% | ▼ −9.24% | $0.6450 (−77.22%) |
May 22, 2026 22w ago | Press Release | $2.83 $2.51 | ▲ +11.30% | ▲ +9.24% | $0.6450 (+77.22%) |
Apr 20, 2026 27w ago | Press Release | $0.2500 $0.1830 | ▼ −26.80% | ▼ −31.00% | $0.6450 (+158.00%) |
Mar 27, 2026 30w ago | Press Release | $0.2390 $0.2240 | ▼ −6.28% | ▼ −18.87% | $0.6450 (+169.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers